 |
 |
 |
Proteonomix, Inc is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives with an initial focus on diabetes and cardiac diseases.
Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include, but are not limited to, cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.
|
Our Mission |
|
Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.
|
 |
Intellectual Properties and Patent Applications. |
|
Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:
|
 |
The Development of Identification Biomarkers
A biomarker is a substance used as an indicator of a biological state which refers to the complete range of genes found in biological structure and processes of the living body, including the nervous system, the endocrine system, and our senses of sight, hearing, taste, smell, and touch. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention) cell derivatives, and cellular proteins.
|
|
Expansion Technology
Proteonomix is developing a unique growth medium that allows expansion far beyond the traditional 10:1 achieved in conventional methods before cellular replication errors make it nonviable. This technology is of benefit to any treatment or process that might be improved by drastically increased concentrations or numbers of cells.
|
|
Cryopreservation
Proteonomix is developing an innovative cryopreservation technique resulting in substantial reduction in lost cells during the freezing and thawing process. This technology is of benefit where it is advantageous to store cellular material for later use, to maintain stock, or to perform long distance transportation.
|
|
Anti-Inflammatory
Proteonomix's StromaCel™ cellular materials has given some indications as a general anti-inflammatory. We are looking for partners wishing to explore this indication for conditions other than myocardial infarction.
|
|
 |
Diabetes Research |
|
Cells that we are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. |
 We have identified stem cells in the human pancreas and have applied for patents for cell surface markers (the molecules present on the surface of each cell which define the cell on what receptors are present - a technique often used to associate cells with certain immune functions) for these pancreatic stem cells as well as methods for their isolation.
Based on the fact that these cells are autologous (from same person) rather than from a non-related donor, we anticipate that the cells that we are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. The company is performing further research in this area with the University of Miami.
|
|
